Introduction {#Sec1}
============

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Multiple risk factors contribute to CVD. A recent standardized case--control study in 52 countries specifically focusing on acute myocardial infarction identified that six risk factors (dyslipidemia, smoking, hypertension, diabetes mellitus, abdominal obesity, and stressful psychosocial factors) account for 90% of myocardial infarctions in men and 94% in women \[[@CR1]\].

Epidemiological surveys have shown that elevated total serum cholesterol (TC) and particular elevated low-density lipoprotein cholesterol (LDL-C) levels are strongly correlated with CHD risk. Many guidelines identify LDL-C as the primary target of cholesterol-lowering therapy and recommend LDL-C goals either numerical or percentage of reduction that are based on the risk category a patient belongs to \[[@CR2], [@CR3]\].

Hypercholesterolemia treatment has shown clear benefits in the primary and secondary prevention of CVD. However, cross-sectional surveys conducted in Europe \[[@CR5], [@CR6]\], and the USA \[[@CR6]--[@CR8]\] on the management of risk factors in patients with CHD have indicated that hypercholesterolemia continues to be inadequately treated \[[@CR4]--[@CR6]\]. Accordingly, many studies are required to assess the current level of under-treatment of hypercholesterolemia, defined as receiving lipid-lowering drug therapy but having uncontrolled TC and/or LDL-C levels and to understand better why patients on pharmacological treatment do not achieve their treatment goals \[[@CR4]--[@CR7]\].

This study is part of the worldwide conducted CEPHEUS studies; Centralized Pan-Middle East Survey on the under-treatment of hypercholesterolemia and the second wave of the Centralized Pan-Middle East Survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS Study in Egypt \[[@CR8]\]. The current study is based on the European Atherosclerosis Society 2011 and the European Society of Cardiology guidelines (EAS/ESC 2011) \[[@CR8]\]. The primary objective is to determine the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals in Egypt according to the EAS/ESC 2011 guidelines. Secondary objectives were to determine the proportions in pre-defined subpopulations including primary and secondary prevention, metabolic syndrome, patients' risk profile category, and identification of determinants (patient and physician characteristics) for patients not reaching their treatment goals and physician characteristics associated with the allocation of different treatment regimens.

Methods {#Sec2}
=======

This is an open-label, observational, non-interventional, multicenter, single-visit cross-sectional survey conducted on patients under lipid-lowering pharmacological treatment. Ninety investigators enrolled 1127 patients on lipid-lowering drugs between April 24, 2014 and August 29, 2015 from Alexandria and Delta Regions in Egypt as part of the CEPHEUS study (NIS-EG-CRE-2012/01). Patients of age 18 years or more receiving lipid-lowering drug for at least 3 months with no dose change for at least 6 weeks signed informed consent to participate and comply with study procedures. Before assessment, after signing informed patient consent, the study questionnaires were completed by patients and investigators. The investigators completed case record forms (CRF) with the patient's demographics, known cardiovascular risk factors, cardiovascular medical history, current lipid-lowering drug treatment, and the reason for the current therapy. Samples were taken for total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, and the ratio of total cholesterol/HDL-C was calculated. The investigators received results within 5 days and completed the CRFs. Under-treatment was defined as receiving lipid-lowering pharmacological treatment and not reaching the LDL-C goals according to the EAS/ESC 2011 guidelines. Non-HDL-C goals was defined as patients with HDL-c \<40 mg/dl and fasting triglycerides \>200 mg/dl.

Among the 1127 enrolled patients, patients with missed LDL-C data (*n* = 231) were excluded from the analysis and results from 896 patients are presented here.

Statistical Analysis {#Sec3}
--------------------

Data of 896 subjects were analyzed in this study. This gives a margin error of ±3.2% at 95% confidence level with expected number of patients achieving treatment goals at 50%.

Number and percentage (*n* and %) presented the categorical data and Chi-square test (or its subsidiaries) was used to obtain *p* values to test significance for difference between groups. Descriptive statistics (mean ± SD) presented the numerical data and Student's *t* test (or its subsidiaries) was used to obtain *p* values to test significance for difference between groups. The calculation of statistics and proportions did not include the missing data. Missing values were presented in separate tables.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study. This article does not contain any new studies with human or animal subjects performed by any of the authors.

Results {#Sec5}
=======

Eight hundred ninety-six subjects were included in the analysis. The mean age was 53.9 ± 10.7 years and 57.6% were male. The main reason of pharmacological therapy was for primary prevention with 59.4% of patients. Statins were the most prescribed agents with 95.2% (853 of 896) of patients; 90% (768) used statins as monotherapy and 10% (85) in combined therapy. Rosuvastatin was the most frequently prescribed statin. It was prescribed to 47.1% (422 of 896) from which 391 were monotherapy and 31 were combined therapy. Other and more detailed demographic data and patients characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients' demography and other variables at the baseline visitParameterVariableValid answer (base)MissingMean and SD or *N* and %Age896053.910.7Weight892492.317.1Height8879168.88.8BMI887932.56.4Waist circumference8573999.521.3Systolic BP8933133.915.9Diastolic BP893384.49.1GenderMale, *n* (%)896051657.6%Female, *n* (%)38042.4%NationalityEgyptian, *n* (%)8963185999.3%Other (Syrian), *n* (%)60.7%EthnicityMiddle Eastern (including North Africa)8692785798.6%Caucasian (including Europe and North America)60.7%Other, *n* (%)60.7%Reason for pharmacological therapyPrimary prevention8762052059.4%Secondary prevention29633.8%Familial hypercholesterolemia606.8%Medical historyHistory of coronary heart disease, *n* (%)896030934.5%History of peripheral artery disease, *n* (%)894211813.2%Cerebrovascular atherosclerotic disease, *n* (%)8960626.9%Established CVD8861037642.4%Comorbid conditionArterial hypertension, *n* (%)8712556164.4%Diabetes, *n* (%)8771944050.2%Family history of premature cardiovascular disease, *n* (%)8455127232.2%Current smoker, *n* (%)8721020723.1%Lab testTotal cholesterol, mg/dl (mmol/l)8960189.347.6HDL-C, mg/dl (mmol/l)896045.213LDL-C, mg/dl (mmol/l)896011541.7Triglycerides, mg/dl (mmol/l)8942150.984Total cholesterol/HDL-C ratio289451.4Glucose, mg/l716180131.961.1HbA1c, % (mmol/mol)89157.11.9Current prescribed medication groupsStatin monotherapy8851176885.7%Statin + fibrate475.2%Statin + ezetimibe353.9%Ezetimibe monotherapy252.8%Fibrate monotherapy70.8%Statin + fibrate + ezetimibe30.3%Current prescribed monotherapy drugsRosuvastatin8851142247.7%Atorvastatin32336.5%Simvastatin829.3%Ezetimibe637.1%Fenofibrate566.3%Fluvastatin101.1%Lovastatin30.3%Pravastatin30.3%Bezafibrate10.1%Gemfibrozil10.1%Undefined statins323.6%

LDL Target Goal Achievement {#Sec6}
---------------------------

Overall, 34.4% (308 of 896 patients) achieved their LDL-C target goal according to the EAS/ESC 2011 guidelines.

A total of 84.7% of low-risk patients achieved target LDL-C goal (\<155 mg/dl), 44.7% of moderate-risk patients achieved target LDL-C goal (\<115 mg/dl), 18.2% of high-risk patients achieved target LDL-C goal (\<100 mg/dl) and 22.3% of very high risk patients achieved target LDL-C goal (\<70 mg/dl or ≥50% reduction).

From the patients who were on rosuvastatin, 33.2% reached the goal with monotherapy and 48.4% with combined therapy, with an overall achievement of 34.2%. From patients who were prescribed treatment for primary prevention: 36.1% achieved LDL-C goal, for secondary prevention 29.9%, and familial hypercholesterolemia 36.2%. (*p* = 0.082). For special populations, the goal was reached for 67.7% of patients with metabolic syndrome and 63.1% without (*p* = 0.087); the goal was reached for 21.6% of patients with diabetes mellitus and 46.5% without (*p* \< 0.001), and finally, goal was reached for 29.6% of patients with arterial hypertension and 42.6% without (*p* \< 0.001) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).Table 2EAS/ESC 2011 risk-profile category, number and percent in each group, lipid-lowering drug, mean and SD of the used dose and number and percent of patients achieving the LD-C treatment goalEAS/ESC 2011 risk profile categoryBaseLipid-lowering agentsAgentDoseAchieved treatment goalBase%NameBaseMeanSD*N*%All896Rosuvastatin44214.65.115234.4Atorvastatin32324.814.811836.5Simvastatin8225.716.22631.7Ezetimibe6315.07.12641.3Fenofibrate56260.064.82137.5Fluvastatin1010.0110.0Pravastatin320.0133.3Lovastatin340.0133.3Bezafibrate100.0Gemfibrozil100.0Undefined statin3221.111.7928.1Very high risk58465.2%Rosuvastatin27216.35.25620.6Atorvastatin21525.114.25726.5Simvastatin5231.020.21019.2Ezetimibe4014.25.11230.0Fenofibrate33253.370.0927.3Fluvastatin800.0Pravastatin220.0150.0Lovastatin100.0Bezafibrate100.0Gemfibrozil100.0Undefined statin2226.711.5313.6High risk222.5%Rosuvastatin1115.07.1218.2Atorvastatin715.07.1228.6Fenofibrate3300.0133.3Simvastatin200.0Ezetimibe200.0Moderate risk17920.0%Rosuvastatin8813.44.84753.4Atorvastatin6123.511.92337.7Simvastatin1623.315.3318.8Ezetimibe1517.510.4853.3Fenofibrate13272.062.6538.5Fluvastatin100.0Lovastatin100.0Pravastatin100.0Undefined statin510.0120.0Low risk11112.4%Rosuvastatin5113.84.94078.4Atorvastatin4025.817.83690.0Simvastatin1221.011.01083.3Fenofibrate7253.372.3685.7Ezetimibe613.35.26100.0Fluvastatin110.01100.0Lovastatin140.01100.0Undefined statin520.012.25100.0Eighty-five patients were on combined-drug therapy. Each patient was on an average of 1.1 drugs Table 3LDL-C target goal achievement according to EAS/ESC 2011 guidelines by different sample determinantsDeterminantVariableBaseAchievedNot achieved*p* valueYes%No%Reason for treatmentPrimary prevention52018936.333163.70.082Secondary prevention2968629.121070.9Familial hypercholesterolemia602338.33761.7Metabolic syndromeMetabolic syndrome49215932.333367.70.087Non-metabolic syndrome40414936.925563.1GenderMale51616732.434967.60.140Female38014137.123962.9Age distribution\<20 years100.01100.00.08120--34 years402152.51947.535--39 years391948.72051.340--44 years893438.25561.845--49 years1324534.18765.950--54 years1706035.311064.755--59 years1635030.711369.360--64 years1223226.29073.865--69 years852630.65969.470--74 years331545.51854.575--79 years10330.0770.0\>79 years12325.0975.0Ethnic originMiddle Eastern (including North Africa)85729734.756065.30.135Caucasian (including Europe and North America)6116.7583.3Others600.06100.0Current smokingSmokers2077134.313665.70.971Non-smokers66522934.443665.6Diabetes mellitusDiabetics4409521.634578.40.000Non-diabetics43720346.523453.5Arterial hypertensionArterial hypertension56116629.639570.40.000Non-arterial hypertension31013242.617857.4Family history of CVDHistory of CVD2729133.518166.50.643No history of CVD57320135.137264.9

Results of the Investigators' Questionnaire {#Sec7}
-------------------------------------------

There were 41.4% of the investigators that mentioned that they use EAS/ESC 2011 guidelines. Most of the investigators use guidelines to set individual cholesterol targets; 94.4% depend on LDL-C as an indicator.

Percent split of prescriptions as reported by investigators was 86.9% for statins, 9.5% for fibrates, and 3.6% for bile acid sequestrants and other drugs. Investigators review their patients mostly every 3 months, and they stated that an average of 55.6% of patients achieved their target cholesterol level. Detailed results of the investigators' questionnaire are presented in Table [4](#Tab4){ref-type="table"}.Table 4Answers of investigators' questionnaire

Results of the Patients' Questionnaire {#Sec8}
--------------------------------------

Eight hundred ninety-two patients returned completed questionnaires. More than 75% of the patients were aware of good and bad cholesterol and mentioned that their doctor told them about their level of cholesterol and target goals and discussed the proper lifestyle, diet, and prescribed medications; 78.5% mentioned that they were satisfied with the information they had about high cholesterol. Results showed that patients were trying to take drugs as they were prescribed but 41% mentioned that they sometimes forgot to take the tablet every day. Most of the patients reported that they did not change the drug they take and few of them (3.3%) reported that they had changed the prescribed drug more than two times. Of the patients, 49% stated that they achieved their target cholesterol level and 75% were satisfied with the treatment they were taking. A strong correlation was found between achieving treatment goal as obtained from CEPHEUS II results and patient compliance as obtained from patients' questionnaire (*p* \< 0.001). Table [5](#Tab5){ref-type="table"} shows detailed results of the patients' questionnaire.Table 5Answers of patients' questionnaire

Discussion {#Sec9}
==========

CEPHEUS surveys in different countries worldwide have aimed to investigate the proportion of patients receiving lipid-lowering drugs and reaching their LDL-C treatment goals according to international guidelines. Compared to the CEPHEUS I survey that had been conducted in Egypt between October 2010 and June 2011, achievement of treatment goal was 32.5% (339 patients out of 1043) according to the NCEP ATP III Updated 2004 guidelines \[[@CR8]\]. CEPHEUS II in Egypt showed a slight improvement in terms of achieving treatment goals compared to CEPHEUS I according to NCEP ATP III Updated 2004 guidelines, as 39.6% (355 out of 896) in CEPHEUS II achieved their LDL-C treatment goal.

CEPHEUS surveys in other countries were reported and the achievement was 57% in combined Western European countries \[[@CR9]\], 49% for combined Asian countries \[[@CR10]\], and 49.1% in combined eight Asian countries (Korea, Taiwan, Thailand, Indonesia, Philippines, Malaysia, Vietnam, Hong Kong SAR, and China) \[[@CR10]\]. The individual results were 52% for South Africa \[[@CR11]\], 49% for Greece \[[@CR7]\], 83% for Hong Kong \[[@CR12]\], 50% for Taiwan \[[@CR13]\], 31.3% for Indonesia \[[@CR14]\], and 53% for Thailand \[[@CR15]\].

Our study (CEPHEUS II) showed that the lowest target LDL-C goal achievements were obtained with diabetes mellitus (21.6%), followed by secondary prevention (29.1%), arterial hypertension (29.6%), and metabolic syndrome (32.3%). On the contrary to previous findings from the CEPHEUS Pan-Asian survey, most of our patients with diabetes mellitus and hypertension did not achieve LDL goals. It is worth mentioning that ezetimibe achieved LDL-C goal with the highest percentage of 41.3% (63 out of 89 patients), in contrast to current knowledge in the literature about statins.

Finally, this study was an observational rather than interventional study, and as such, it suffers from many limitations. Most of the variables that may affect treatment goals were considered; however, many variables were not counted, such as differences in clinical practice between study investigators, lifestyle, diet factors, adverse events, and socioeconomic status.

Conclusions {#Sec10}
===========

Statins are the most frequently used lipid-lowering drugs and have a significant impact on achieving target LDL-C goals. As per the current CEPHEUS II results, hypercholesterolemia is still not being effectively managed in many at-risk patients in Egypt. The majority of patients enrolled in the study, all of whom were being actively treated with lipid-lowering medication, were considered at high risk of a cardiovascular event; hypercholesterolemia was particularly poorly managed in this group. Initiatives are needed to improve physicians' management of these patients with more focus on their risk profiles. Patient compliance to treatment is still urgently needed.
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